BTIG analyst Sean Lavin upgraded AtriCure to Buy from Neutral with a $35 price target following the recent share slide, telling investors in a research note that its valuation warrants a second look. Lavin says that at the current valuation, he believes investors can be rewarded through quarterly beats and “enthusiasm” ahead of Converge data and notes that fundamentals have improved as the open business has stabilized.
https://thefly.com/landingPageNews.php?id=2887153
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.